Skip to main content
Erschienen in: Breast Cancer Research and Treatment 2/2022

21.05.2022 | Epidemiology

Insulin resistance and weight gain in women treated for early stage breast cancer

verfasst von: Grace Makari-Judson, Richard Viskochil, Deborah Katz, Ruth Barham, Wilson C. Mertens

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Both weight gain and insulin resistance have been associated with poorer prognosis in women receiving adjuvant therapy for early stage breast cancer, however, interactions between weight gain and insulin resistance have not been explored longitudinally throughout the breast cancer treatment continuum.

Methods

One hundred non-diabetic women with early stage breast cancer receiving adjuvant chemotherapy and /or hormonal therapy were enrolled in this prospective, observational study. Metrics of weight, body composition (BMI, waist/hip circumference ratio (WHR)), and cardiometabolic health (fasting insulin, glucose and triglycerides) were obtained prior to adjuvant therapy (baseline) and repeated 6, 12, and 24 months post-diagnosis. Insulin resistance was calculated using the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR).

Results

Complete data were available for 95 participants. Compared to baseline, body weight was significantly higher at the 12-month time-point (75.3 ± 15.7 vs. 76.2 ± 16.7, p = 0.03), however there was no difference in waist circumference (p = 0.96) or WHR (p = 0.52). HOMA-IR tended to increase 6 months after diagnosis (2.36 ± 2.17 vs. 2.70 ± 2.83, p = 0.06), largely driven by adverse responses in patients treated with chemotherapy (mean change + 0.53 (chemotherapy) vs − 0.64 (no chemotherapy), p = 0.005). Despite 12-month weight gain, the 6-month increase in HOMA-IR was fully abrogated 12 months after diagnosis.

Conclusion

Breast cancer patients experience small but significant weight gain in the year following diagnosis, and those who receive chemotherapy experience significant short-term metabolic impairments suggestive of insulin resistance. While the acute insulin resistance appears to attenuate over time, the long-term ramifications are unclear and may help explain weight gain in this population.
Literatur
11.
Zurück zum Zitat Iyengar NM, Arthur R, Manson JE, Chlebowski RT, Kroenke CH, Peterson L, Cheng TD, Feliciano EC, Lane D, Luo J, Nassir R, Pan K, Wassertheil-Smoller S, Kamensky V, Rohan TE, Dannenberg AJ (2019) Association of body fat and risk of breast cancer in postmenopausal women with normal body mass index: a secondary analysis of a randomized clinical trial and observational study. JAMA Oncol 5(2):155–163. https://doi.org/10.1001/jamaoncol.2018.5327CrossRefPubMed Iyengar NM, Arthur R, Manson JE, Chlebowski RT, Kroenke CH, Peterson L, Cheng TD, Feliciano EC, Lane D, Luo J, Nassir R, Pan K, Wassertheil-Smoller S, Kamensky V, Rohan TE, Dannenberg AJ (2019) Association of body fat and risk of breast cancer in postmenopausal women with normal body mass index: a secondary analysis of a randomized clinical trial and observational study. JAMA Oncol 5(2):155–163. https://​doi.​org/​10.​1001/​jamaoncol.​2018.​5327CrossRefPubMed
12.
Zurück zum Zitat Rock CL, Flatt SW, Laughlin GA, Gold EB, Thomson CA, Natarajan L, Jones LA, Caan BJ, Stefanick ML, Hajek RA, Al-Delaimy WK, Stanczyk FZ, Pierce JP, Womens Health Eating and Living Study Group (2008) Reproductive steroid hormones and recurrence-free survival in women with a history of breast cancer. Cancer Epidemiol Biomark Prev 17(3):614–620. https://doi.org/10.1158/1055-9965-07-0761CrossRef Rock CL, Flatt SW, Laughlin GA, Gold EB, Thomson CA, Natarajan L, Jones LA, Caan BJ, Stefanick ML, Hajek RA, Al-Delaimy WK, Stanczyk FZ, Pierce JP, Womens Health Eating and Living Study Group (2008) Reproductive steroid hormones and recurrence-free survival in women with a history of breast cancer. Cancer Epidemiol Biomark Prev 17(3):614–620. https://​doi.​org/​10.​1158/​1055-9965-07-0761CrossRef
15.
Zurück zum Zitat Bell KE, Di Sebastiano KM, Vance V, Hanning R, Mitchell A, Quadrilatero J, Russell C, Dubin JA, Bahl M, Califaretti N, Campbell C, Mourtzakis M (2014) A comprehensive metabolic evaluation reveals impaired glucose metabolism and dyslipidemia in breast cancer patients early in the disease trajectory. Clin Nutr 33(3):550–557. https://doi.org/10.1016/j.clnu.2013.08.001CrossRefPubMed Bell KE, Di Sebastiano KM, Vance V, Hanning R, Mitchell A, Quadrilatero J, Russell C, Dubin JA, Bahl M, Califaretti N, Campbell C, Mourtzakis M (2014) A comprehensive metabolic evaluation reveals impaired glucose metabolism and dyslipidemia in breast cancer patients early in the disease trajectory. Clin Nutr 33(3):550–557. https://​doi.​org/​10.​1016/​j.​clnu.​2013.​08.​001CrossRefPubMed
21.
Zurück zum Zitat Dieli-Conwright CM, Courneya KS, Demark-Wahnefried W, Sami N, Lee K, Buchanan TA, Spicer DV, Tripathy D, Bernstein L, Mortimer JE (2018) Effects of aerobic and resistance exercise on metabolic syndrome, sarcopenic obesity, and circulating biomarkers in overweight or obese survivors of breast cancer: a randomized controlled trial. J Clin Oncol 36(9):875–883. https://doi.org/10.1200/JCO.2017.75.7526CrossRefPubMedPubMedCentral Dieli-Conwright CM, Courneya KS, Demark-Wahnefried W, Sami N, Lee K, Buchanan TA, Spicer DV, Tripathy D, Bernstein L, Mortimer JE (2018) Effects of aerobic and resistance exercise on metabolic syndrome, sarcopenic obesity, and circulating biomarkers in overweight or obese survivors of breast cancer: a randomized controlled trial. J Clin Oncol 36(9):875–883. https://​doi.​org/​10.​1200/​JCO.​2017.​75.​7526CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Irwin ML, Varma K, Alvarez-Reeves M, Cadmus L, Wiley A, Chung GG, Dipietro L, Mayne ST, Yu H (2009) Randomized controlled trial of aerobic exercise on insulin and insulin-like growth factors in breast cancer survivors: the Yale Exercise and Survivorship study. Cancer Epidemiol Biomark Prev 18(1):306–313. https://doi.org/10.1158/1055-9965.EPI-08-0531CrossRef Irwin ML, Varma K, Alvarez-Reeves M, Cadmus L, Wiley A, Chung GG, Dipietro L, Mayne ST, Yu H (2009) Randomized controlled trial of aerobic exercise on insulin and insulin-like growth factors in breast cancer survivors: the Yale Exercise and Survivorship study. Cancer Epidemiol Biomark Prev 18(1):306–313. https://​doi.​org/​10.​1158/​1055-9965.​EPI-08-0531CrossRef
28.
Zurück zum Zitat Sadim M, Xu Y, Selig K, Paulus J, Uthe R, Agarwl S, Dubin I, Oikonomopoulou P, Zaichenko L, McCandlish SA, Van Horn L, Mantzoros C, Ankerst DP, Kaklamani VG (2017) A prospective evaluation of clinical and genetic predictors of weight changes in breast cancer survivors. Cancer 123(13):2413–2421. https://doi.org/10.1002/cncr.30628CrossRefPubMed Sadim M, Xu Y, Selig K, Paulus J, Uthe R, Agarwl S, Dubin I, Oikonomopoulou P, Zaichenko L, McCandlish SA, Van Horn L, Mantzoros C, Ankerst DP, Kaklamani VG (2017) A prospective evaluation of clinical and genetic predictors of weight changes in breast cancer survivors. Cancer 123(13):2413–2421. https://​doi.​org/​10.​1002/​cncr.​30628CrossRefPubMed
Metadaten
Titel
Insulin resistance and weight gain in women treated for early stage breast cancer
verfasst von
Grace Makari-Judson
Richard Viskochil
Deborah Katz
Ruth Barham
Wilson C. Mertens
Publikationsdatum
21.05.2022
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2022
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-022-06624-1

Weitere Artikel der Ausgabe 2/2022

Breast Cancer Research and Treatment 2/2022 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.